NUFORMIX PLC

Share Issue/Capital Change • Dec 6, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4909Y

Nuformix PLC

06 December 2017

Nuformix plc

("Nuformix" or "the Company")

Grant of Warrants at 6p per share

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that Warrants over new ordinary shares have been granted to Beaufort Securities Limited, and  have vested in accordance with the terms agreed with its recent appointment as the Company's broker:

Warrants over no. of shares	Exercise price per share	Lapse date
1,000,000	6 pence	20 November 2020

Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX

and www.nuformix.com

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

ENDS

Enquiries:

Nuformix plc Dan Gooding, Chief Executive Officer	+44 (0)1223 423667
Beaufort Securities Limited (Joint Broker) Jon Belliss	+44 (0)20 7382 8300
Gable Communications Ltd John Bick / Justine James	+44 (0)20 7193 7463

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs.   Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.  Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEEAAASESLXFAF